Research programme: photodynamic therapy - Novartis Ophthalmics/Destiny Pharma

Drug Profile

Research programme: photodynamic therapy - Novartis Ophthalmics/Destiny Pharma

Alternative Names: Photodynamic therapy research programme: Novartis Ophthalmics/Destiny Pharma

Latest Information Update: 26 Apr 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Destiny Pharma; Novartis Ophthalmics
  • Developer Destiny Pharma
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Eye disorders

Most Recent Events

  • 26 Apr 2007 Discontinued - Preclinical for Eye disorders in United Kingdom (unspecified route)
  • 23 Jan 2001 CIBA Vision is now called Novartis Ophthalmics
  • 09 Dec 1999 Preclinical development for Eye disorders in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top